GSK and Dong-A - Top 5 Emerging Market Deals

Who: GlaxoSmithKline
With: Dong-A Pharmaceuticals
Where: South Korea

Deal Size: $114 million

Details: In May GSK bought itself a 9.9 percent stake in Dong-A Pharmaceuticals, the number one pharma and OTC drugmaker in the fast-growing South Korean market. As part of the agreement, Dong-A will co-promote a roster of GSK primary-care products.

The Korean pharmaceutical market has been experience impressive pharma market growth (13.9% CAGR 2006-08), and was the 13th largest pharmaceutical market in the world in 2008. The market is expected to continue its double-digit growth spurt through to 2012. Prior to the deal, GSK was ranked fifth amount South Korean drugmakers with 2009 sales of $333.6 million. 

GSK and Dong-A - Top 5 Emerging Market Deals
Read more on

Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.